A study of the transplacental transfer and the mammary excretion of cefoxitin in humans.
Cefoxitin is a new semisynthetic cephamycin derivative with broad bactericidal activities. In order to determine the extent of the transplacental transfer of cefoxitin, 35 pregnant women received 1 Gm cefoxitin intramuscularly 15 to 180 minutes before normal or Caesarean delivery. Cefoxitin was measured microbiologically in maternal blood (multiple-time samples), umbilical blood (one-time sample), and amniotic fluid in the cases of Caesarean sections. The mammary excretion of cefoxitin injected at the same dose was investigated by measuring cefoxitin in the milk of 16 nursing mothers. In the maternal blood, a peak plasma level of approximately 25 microgram/ml was reached 30 minutes after the 1-Gm intramuscular injection. A clear-cut passage of cefoxitin in the umbilical cord blood was demonstrated. In the fetal blood, a peak level of 15 microgram/ml was obtained 45 minutes after the injection. No cefoxitin was detectable in any of the milk samples from 30 minutes to 24 hours after the 1-Gm intramuscular injection.
D000293:Adolescent; D000328:Adult; D000653:Amniotic Fluid / Q000032:analysis; D002440:Cefoxitin / Q000378:metabolism*; D005260:Female; D005312:Fetal Blood / Q000032:analysis; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D008895:Milk, Human / Q000378:metabolism*; D010920:Placenta / Q000378:metabolism*; D011247:Pregnancy
D002440:Cefoxitin